Zion Research has published a new report titled “Human Insulin Market by Product (Drug and Drug Delivery Devices) for Type 1 Diabetes, Type 2 Diabetes Application -Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021” According to the report, the global Human Insulin market accounted for USD 27.00 billion in 2015 and is expected to reach USD 43.6 billion by 2021, growing at a CAGR of around 8.3% between 2016 and 2021.
Request Free Sample copy of Research Report @ https://www.zionmarketresearch.com/sample/human-insulin-market
The global human insulin market is expected to witness significant growth during the forecast period. This growth is attributed due to increasing risk of diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. An insulin regimen is often required in the treatment of gestational diabetes and diabetes-associated with certain conditions or syndromes (e.g.pancreatic diseases, drug- or chemical-induced diabetes, endocrinopathies, insulin-receptor disorders, certain genetic syndromes). In all instances of insulin use, the insulin dosage must be individualized and balanced with medical nutrition therapy and exercise.
Browse detail report with in-depth TOC @ https://www.zionmarketresearch.com/report/human-insulin-market
In terms of drugs, biosimilars drugs were expected to account for the largest market share of the human insulin market in the upcoming forecast period. Demand for biosimilar drugs is strong in both developed and developing countries due to its low-cost therapy. This is driven by the need for the best valuable treatment, which can often be expensive. Biosimilar insulin drug may offer a less-costly alternative to existing human insulin biologics.
On the basis of drug delivery device, the pens segment is expected to account for the largest market share in 2015 followed by syringe and pen Needle. This growth can be endorsed due to growing market focus of pen manufacturers on emerging countries such as China, India, and Brazil. Insulin pens look similar to oversized ink pens, making them a potentially convenient and discreet way of carrying insulin which makes him one of the demanding factors over the other market.
Request a customized copy of report @ https://www.zionmarketresearch.com/custom/101
Key market players of human insulin market include Eli Lilly, GlaxoSmithCline, Biocon, Sanofi-Aventis, Julphar, Novo Nordisk, SemBioSys, Ypsomed AG and Wockhardt.
This report segments the global human insulin market as follows:
Human Insulin Market: Product Segment Analysis
- Insulin Analogs and Biosimilars
- Human Insulin Biologics
- Drug Delivery Devices
- Pen Needles
Human Insulin Market: Application Segment Analysis
- Insulin dependent diabetes mellitus (Type 1)
- Non-Insulin dependent diabetes mellitus (Type 2)
Human Insulin Market: Regional Segment Analysis
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
For More Inquiry contact our sales Team @ email@example.com
Zion Market Research is an obligated company. We create futuristically, cutting edge, informative reports ranging from industry reports, a company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
4283, Express Lane,
Sarasota, Florida 34249, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651